Program

Indication

Discovery

Preclinical

Phase 1 Safety
Dose-Escalation

Phase 1b
Dose-Expansion/
Efficacy Signal

AB928 (Dual Adenosine Receptor Antagonist) LEARN MORE

AB928+AB122

CRPC, RCC

Title

75%

AB928+AB122+Carbo/Pem

NSCLC

Title

65%

AB928+mFOLFOX

CRC, GEC1

Title

75%

AB928+PLD2

TNBC, Ovarian1

Title

75%

AB928+PLD2+IPI-549

TNBC

Title

52%

AB680 (Small Molecule CD73 Inhibitor) LEARN MORE

AB680+AB122+Gem/nab-paclitaxel

Pancreatic

2H19: Initiate Ph1 Safety Dose-Escalation

52%

AB122 (Anti-PD-1 Antibody) LEARN MORE

AB122

Biomarker-selected
(tumor-type agnostic)

2H19: Initiate Safety & Efficacy Evaluations

75%

AB154 (Anti-TIGIT Antibody) LEARN MORE

AB154+AB122

NSCLC

Title

65%

Discovery and Preclinical Small Molecules

AB610 (PI3Kγ Inhibitor)

Oncology Indications

Title

20%

HIF-2α Antagonist

Oncology Indications

Title

15%

Axl Inhibitor

Oncology Indications

Title

10%

PAK4 Inhibitor

Oncology Indications

Title

5%
  1. Potential Investigator-Sponsored Trial(s) (IST).
  2. Pegylated liposomal doxorubicin.